-
1دورية أكاديمية
المؤلفون: Hensley, Martee L, Enserro, Danielle, Hatcher, Helen, Ottevanger, Petronella B, Krarup-Hansen, Anders, Blay, Jean-Yves, Fisher, Cyril, Moxley, Katherine M, Lele, Shashikant B, Lea, Jayanthi S, Tewari, Krishnansu S, Thaker, Premal H, Zivanovic, Oliver, O'Malley, David M, Robison, Katina, Miller, David S
المصدر: Journal of Clinical Oncology. 36(33)
مصطلحات موضوعية: Clinical Trials and Supportive Activities, Clinical Research, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/69j303n2Test
-
2دورية أكاديمية
المؤلفون: Hendrikse, C. S.E., Theelen, P. M.M., van der Ploeg, P., Westgeest, H. M., Boere, I. A., Thijs, A. M.J., Ottevanger, P. B., van de Stolpe, A., Lambrechts, S., Bekkers, R. L.M., Piek, J. M.J.
المصدر: Hendrikse , C S E , Theelen , P M M , van der Ploeg , P , Westgeest , H M , Boere , I A , Thijs , A M J , Ottevanger , P B , van de Stolpe , A , Lambrechts , S , Bekkers , R L M & Piek , J M J 2023 , ' The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer : A systematic review and meta-analysis ' , Gynecologic Oncology , vol. 171 , pp. 83-94 . https://doi.org/10.1016/j.ygyno.2023.01.038Test
مصطلحات موضوعية: /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1016/j.ygyno.2023.01.038Test
https://pure.eur.nl/en/publications/a6825ade-9eca-44ad-8895-849e27b04b76Test
https://pure.eur.nl/ws/files/85669738/The_potential_of_RAS_RAF_MEKERK_MAPK_signaling_pathway_inhibitors_in_ovarian_cancer.pdfTest
http://www.scopus.com/inward/record.url?scp=85148715111&partnerID=8YFLogxKTest -
3دورية أكاديمية
المؤلفون: Post, C C B, Westermann, A M, Boere, I A, Witteveen, P O, Ottevanger, P B, Sonke, G S, Lalisang, R I, Putter, H, Meershoek-Klein Kranenbarg, E, Braak, J P B M, Creutzberg, C L, Bosse, T, Kroep, J R
المساهمون: MS Radiotherapie, MS Medische Oncologie, Cancer
مصطلحات موضوعية: Durvalumab, Endometrial cancer, Immune checkpoint inhibitor, Olaparib, PARP inhibitor, Obstetrics and Gynaecology, Oncology, Journal Article
وصف الملف: application/pdf
-
4دورية أكاديمية
المؤلفون: Heimovaara, Joosje H., Boere, Ingrid A., de Haan, Jorine, van Calsteren, Kristel, Amant, Frédéric, van Zuylen, L., Lok, Christine A.R., Lok, C. A.R., Amant, F., Beerendonk, C. C.M., Bellido-Casado, M., Beltman, J. J., Bos, M. E.M.M., Duvekot, J. J., Gerestein, C. G., Gordijn, S., de Groot, C. J.M., van Grotel, M., Han, S. N., Heeres, B. C., van den Heuvel-Eibrink, M. M., Houwink, A., Huitema, D. R., Koken, Ph W., Koppert, L. B., Lugtenburg, P. J., Ottevanger, P. B., Painter, R. C., Poortmans, P. M.P., Roes, E. M., van der Scheer, L., Schröder, C. P., Suelmann, B. B.M., Suijkerbuijk, K. P.M., van Tienhoven, G., van Trommel, N. E., Trum, J. W., van der Velden, J., Vriens, I. J.H., Witteveen, P. O.
المصدر: the Dutch Advisory Board for Cancer during Pregnancy , Heimovaara , J H , Boere , I A , de Haan , J , van Calsteren , K , Amant , F , van Zuylen , L , Lok , C A R , Lok , C A R , van Zuylen , L , Boere , I A , Amant , F , Beerendonk , C C M , Bellido-Casado , M , Beltman , J J , Bos , M E M M , Duvekot , J J , Gerestein , C G , Gordijn , S ....
مصطلحات موضوعية: /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, SDG 3 - Good Health and Well-being
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1016/j.ejca.2022.04.040Test
https://pure.eur.nl/en/publications/e057f2ff-1abd-4f0d-9bfe-f30e909416ddTest
https://pure.eur.nl/ws/files/57136519/Ten_year_experience_of_a_national_multidisciplinary_tumour_board_for_cancer_and_pregnancy_in_the_Netherlands.pdfTest
http://www.scopus.com/inward/record.url?scp=85132449987&partnerID=8YFLogxKTest -
5دورية أكاديمية
المؤلفون: Post, C. C.B., Westermann, A. M., Boere, I. A., Witteveen, P. O., Ottevanger, P. B., Sonke, G. S., Lalisang, R. I., Putter, H., Meershoek-Klein Kranenbarg, E., Braak, J. P.B.M., Creutzberg, C. L., Bosse, T., Kroep, J. R.
المصدر: Post , C C B , Westermann , A M , Boere , I A , Witteveen , P O , Ottevanger , P B , Sonke , G S , Lalisang , R I , Putter , H , Meershoek-Klein Kranenbarg , E , Braak , J P B M , Creutzberg , C L , Bosse , T & Kroep , J R 2022 , ' Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial) ' , Gynecologic Oncology , vol. 165 , no. 2 , pp. 223-229 . ....
مصطلحات موضوعية: /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1016/j.ygyno.2022.02.025Test
https://pure.eur.nl/en/publications/26fa5fad-d2e5-4d75-ba74-f9853331463cTest
https://pure.eur.nl/ws/files/86525174/1_s2.0_S0090825822001457_main.pdfTest
http://www.scopus.com/inward/record.url?scp=85126284877&partnerID=8YFLogxKTest -
6دورية أكاديمية
المؤلفون: van Gerwena M., Vandenbrouckec T., Verheeckec M., Van Calsteren K., Halaska M. J., Fumagalli M., Fruscio R., Gandhi A., Veening M., Lagae L., Ottevanger P. B., Voigt J. -U., de Haan J., Gziri M. M., Maggen C., Mertens L., Naulaers G., Claes L., Amant F.
المساهمون: M. van Gerwena, T. Vandenbrouckec, M. Verheeckec, K. Van Calsteren, M.J. Halaska, M. Fumagalli, R. Fruscio, A. Gandhi, M. Veening, L. Lagae, P.B. Ottevanger, J.-. Voigt, J. de Haan, M.M. Gziri, C. Maggen, L. Merten, G. Naulaer, L. Clae, F. Amant
مصطلحات موضوعية: Antineoplastic agent, Child development, Follow-up studie, High-risk, Infant, Pregnancy, Prenatal Exposure Delayed Effects, Settore MED/38 - Pediatria Generale e Specialistica
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32939376; info:eu-repo/semantics/altIdentifier/wos/WOS:000583229100170; volume:32; firstpage:1; lastpage:12; numberofpages:12; journal:DATA IN BRIEF; http://hdl.handle.net/2434/781759Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85089998734
-
7دورية أكاديمية
المؤلفون: Vandenbroucke T., Verheecke M., van Gerwen M., Van Calsteren K., Halaska M. J., Fumagalli M., Fruscio R., Gandhi A., Veening M., Lagae L., Ottevanger P. B., Voigt J. -U., de Haan J., Gziri M. M., Maggen C., Mertens L., Naulaers G., Claes L., Amant F., Blommaert J., Dekrem J., Goffin F., Rigo V., Fontana C., Mosca F., Passera S., Picciolini O., Scarfone G., Peccatori F. A., Boffi M. L., Delle Marchette M., Nacinovich R., Lok C., Wolters V., Boere I., Witteveen E., Schroder C., de Groot C., van Grotel M., van den Heuvel-Eibrink M., Babkova A., Drochytek V.
المساهمون: T. Vandenbroucke, M. Verheecke, M. van Gerwen, K. Van Calsteren, M.J. Halaska, M. Fumagalli, R. Fruscio, A. Gandhi, M. Veening, L. Lagae, P.B. Ottevanger, J.-. Voigt, J. de Haan, M.M. Gziri, C. Maggen, L. Merten, G. Naulaer, L. Clae, F. Amant, J. Blommaert, J. Dekrem, F. Goffin, V. Rigo, C. Fontana, F. Mosca, S. Passera, O. Picciolini, G. Scarfone, F.A. Peccatori, M.L. Boffi, M. Delle Marchette, R. Nacinovich, C. Lok, V. Wolter, I. Boere, E. Witteveen, C. Schroder, C. de Groot, M. van Grotel, M. van den Heuvel-Eibrink, A. Babkova, V. Drochytek
مصطلحات موضوعية: Antineoplastic agent, Child development, Follow-up studie, High risk, Infant, Pregnancy, Prenatal exposure delayed effects, Settore MED/38 - Pediatria Generale e Specialistica
العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000574846800007; volume:138; firstpage:57; lastpage:67; numberofpages:11; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/2434/781761Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85089819452
-
8دورية أكاديمية
المؤلفون: Aydemirli, M D, Kapiteijn, E, Ferrier, K R M, Ottevanger, P B, Links, T P, van der Horst-Schrivers, A N A, Broekman, K E, Groenwold, R H H, Zwaveling, J
المصدر: Aydemirli , M D , Kapiteijn , E , Ferrier , K R M , Ottevanger , P B , Links , T P , van der Horst-Schrivers , A N A , Broekman , K E , Groenwold , R H H & Zwaveling , J 2020 , ' Effectiveness and toxicity of lenvatinib in refractory thyroid cancer : Dutch real-life data ' , European Journal of Endocrinology , vol. 182 , no. 2 , pp. 131-138 . https://doi.org/10.1530/EJE-19-0763Test
مصطلحات موضوعية: Adult, Aged, 80 and over, Antineoplastic Agents/therapeutic use, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Phenylurea Compounds/adverse effects, Quinolines/adverse effects, Retrospective Studies, Thyroid Neoplasms/drug therapy
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1530/EJE-19-0763Test
https://hdl.handle.net/11370/95846c5d-1a76-4caa-926e-65a4053d0ad1Test
https://research.rug.nl/en/publications/95846c5d-1a76-4caa-926e-65a4053d0ad1Test
https://pure.rug.nl/ws/files/116876227/Effectiveness_and_toxicity_of_lenvatinib_in_refractory_thyroid_cancer_Dutch_real_life_data.pdfTest -
9دورية أكاديمية
المؤلفون: Timmermans, Maite, Sonke, G. S., Van de Vijver, K. K., Ottevanger, P. B., Nijman, H. W., van der Aa, M. A., Kruitwagen, R. F. P. M.
المصدر: Timmermans , M , Sonke , G S , Van de Vijver , K K , Ottevanger , P B , Nijman , H W , van der Aa , M A & Kruitwagen , R F P M 2019 , ' Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer ' , International Journal of Gynecological Cancer , vol. 29 , no. 2 , pp. 392-397 . https://doi.org/10.1136/ijgc-2018-000100Test
مصطلحات موضوعية: IMMORTAL TIME BIAS, EPITHELIAL OVARIAN, PRIMARY SURGERY, FALLOPIAN-TUBE, NEOADJUVANT CHEMOTHERAPY, SURGICAL CYTOREDUCTION, SURVIVAL, DISEASE, IMPACT, TUMOR
وصف الملف: application/pdf
العلاقة: https://cris.maastrichtuniversity.nl/en/publications/6b23b555-dfa8-40ad-9714-c8f3acade395Test
الإتاحة: https://doi.org/10.1136/ijgc-2018-000100Test
https://cris.maastrichtuniversity.nl/en/publications/6b23b555-dfa8-40ad-9714-c8f3acade395Test
https://cris.maastrichtuniversity.nl/ws/files/112889947/Kruitwagen_2019_Localization_of_distant_metastases_defines.pdfTest -
10دورية أكاديمية
المؤلفون: de Boer S. M., Powell M. E., Mileshkin L., Katsaros D., Bessette P., Haie-Meder C., Ottevanger P. B., Ledermann J. A., Khaw P., Colombo A., Fyles A., Baron M. -H., Jurgenliemk-Schulz I. M., Kitchener H. C., Nijman H. W., Wilson G., Brooks S., Carinelli S., Provencher D., Hanzen C., Lutgens L. C. H. W., Smit V. T. H. B. M., Singh N., Do V., D'Amico R., Nout R. A., Feeney A., Verhoeven-Adema K. W., Putter H., Creutzberg C. L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P. J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Kruitwagen R. F. P. M., Hollema H., Pras E., Snyers A., Stalpers L., Jobsen J. J., Slot A., Mens J. -W. M., Stam T. C., Van Triest B., Van der Steen - Banasik E. M., De Winter K. A. J., Quinn M. A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Gribaudo S., Lissoni A. A., Ferrero A., Artioli G., Davidson C., McLachlin C. M., Ghatage P., Rittenberg P. V. C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., Tubiana-Mathieu N.
المساهمون: de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, P, Ledermann, J, Khaw, P, Colombo, A, Fyles, A, Baron, M, Jurgenliemk-Schulz, I, Kitchener, H, Nijman, H, Wilson, G, Brooks, S, Carinelli, S, Provencher, D, Hanzen, C, Lutgens, L, Smit, V, Singh, N, Do, V, D'Amico, R, Nout, R, Feeney, A, Verhoeven-Adema, K, Putter, H, Creutzberg, C, Mccormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, P, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Kruitwagen, R, Hollema, H, Pras, E, Snyers, A, Stalpers, L, Jobsen, J, Slot, A, Mens, J, Stam, T, Van Triest, B, Van der Steen - Banasik, E, De Winter, K, Quinn, M, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Gribaudo, S, Lissoni, A, Ferrero, A, Artioli, G, Davidson, C, Mclachlin, C, Ghatage, P, Rittenberg, P, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, Tubiana-Mathieu, N
مصطلحات موضوعية: Aged, Antineoplastic Combined Chemotherapy Protocol, Australia, Canada, Carboplatin, Carcinoma, Endometrioid, Cisplatin, Endometrial Neoplasm, Europe, Female, Human, Lymph Node Excision, Middle Aged, Neoplasm Grading, Neoplasm Staging, New Zealand, Paclitaxel, Radiotherapy, Adjuvant, Risk Factor, Time Factor, Treatment Outcome, Chemoradiotherapy, Dose Fractionation, Radiation, Gynecologic Surgical Procedures
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29449189; info:eu-repo/semantics/altIdentifier/wos/WOS:000426466100046; volume:19; issue:3; firstpage:295; lastpage:309; numberofpages:15; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/10281/244633Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85041954770; http://www.journals.elsevier.com/the-lancet-oncologyTest/
الإتاحة: https://doi.org/10.1016/S1470-2045Test(18)30079-2
http://hdl.handle.net/10281/244633Test
http://www.journals.elsevier.com/the-lancet-oncologyTest/